| Date Filed | Type | Description |
| 10/13/2023 |
10-Q
| Quarterly Report for the period ended September 30, 2023 |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/23/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Other Events Interactive Data |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.2% stake in Aileron Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/17/2022 |
4
| Morrison Jodie Pope (Director) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 54,500 options to buy
@ $0.397, valued at
$21.6k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Sigal Nolan Howard (Director) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 54,500 options to buy
@ $0.397, valued at
$21.6k
|
|
| 06/17/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/17/2022 |
4
| Ambros Reinhard J. (Director) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 54,500 options to buy
@ $0.397, valued at
$21.6k
|
|
| 06/17/2022 |
4
| Bailey Jeffrey Allen (Director) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 54,500 options to buy
@ $0.397, valued at
$21.6k
|
|
| 06/17/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/13/2022 |
DEL AM
| Form DEL AM - Delaying amendment: |
| 06/08/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/15/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/15/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/30/2022 |
4/A
| Aivado Manuel (See Remarks) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 1,133,000 options to buy
@ $0.48, valued at
$543.8k
|
|
| 03/30/2022 |
4/A
| Vukovic Vojo (Chief Medical Officer) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 150,000 options to buy
@ $0.48, valued at
$72k
|
|
| 03/30/2022 |
4/A
| Wanstall Rick (See Remarks) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 393,000 options to buy
@ $0.48, valued at
$188.6k
|
|
| 03/30/2022 |
4/A
| Annis Allen (SVP, Research) has filed a Form 4 on AILERON THERAPEUTICS INC|
Txns:
| Granted 313,000 options to buy
@ $0.48, valued at
$150.2k
|
|
|